Key result
Abnormal baseline LVGLS flags ~42% cardiotoxicity risk in pediatric patients receiving anthracyclines.
Why the study?
Anthracycline-induced cardiotoxicity is a relevant adverse effect in cancer treatment, especially in leukemia and lymphoma, where early and subclinical detection is critical.
Does echocardiographic assessment with LVGLS enable early detection of subclinical cardiotoxicity in pediatric cancer patients treated with anthracyclines?
Cross-Sectional (n=45)
No
Does echocardiographic assessment with LVGLS enable early detection of subclinical cardiotoxicity in pediatric cancer patients treated with anthracyclines?
Echocardiographic assessment of LVGLS provides a highly sensitive method for the early, subclinical detection of anthracycline-induced cardiotoxicity in pediatric cancer patients with preserved ejection fraction.
Answers are grounded in this paper and cite their sources.
Abnormal baseline GLS may flag high-risk pediatric anthracycline recipients despite preserved EF; hypothesis-generating and should not yet change practice.
OBJECTIVE: To evaluate the early detection of cardiotoxicity using echocardiography in children and adolescents with cancer treated with anthracyclines. METHODS: This cross-sectional study was conducted in a tertiary pediatric oncology center in Northeastern Brazil between January 2018 and December 2022. Eligible participants were under 19-year-old patients with cancer treated with anthracyclines presenting left ventricular ejection fraction ≥55% (assessed using the biplane Simpson's method) and abnormal left ventricular global longitudinal strain. RESULTS: A total of 45 patients meeting the inclusion criteria were included. Among them, 19 patients (42.2%) showed reduced ejection fraction or left ventricular global longitudinal strain (or both) compared with baseline values, and 57.9% were asymptomatic. The most prevalent cancer was leukemia (55.5%), followed by lymphoma (20.0%). A total of 75.6% of participants were undergoing cancer treatment at the time of diagnosis of cardiotoxicity. An isolated left ventricular ejection fraction reduction occurred in 26.3% of patients, isolated left ventricular global longitudinal strain reduction in 47.4% of patients, and both alterations were experienced by 26.3% of patients. CONCLUSIONS: Anthracycline-induced cardiotoxicity is a relevant adverse effect in cancer treatment, especially in patients with leukemia and lymphoma. Echocardiography, especially the assessment of left ventricular global longitudinal strain, plays a critical role in the early and subclinical detection of cardiotoxicity in pediatric patients.
No takes yet. Share an insight, caveat, or question.
Martins et al. (2026) conducted a cross-sectional in Cancer in children and adolescents treated with anthracyclines (n=45). Anthracyclines was evaluated on Echocardiographic cardiotoxicity (reduction in LVEF ≥10% or to <55%, or reduction in LVGLS ≥15% compared with baseline). Among pediatric cancer patients treated with anthracyclines with preserved ejection fraction but abnormal baseline global longitudinal strain, 42.2% developed echocardiographic cardiotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: